Form D · Biotechnology
Nirrin Technologies, Inc.
Billerica, MA · CIK 0001889145
Offering snapshot reported Jun 15, 2026 · SEC filing
- Reported sold
- $6.7M Offering amount: $9.71M
- Investors reported
- 23 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 23, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 15, 2026 | Initial | $6,699,781 | No comparison | 23 | SEC filing |
| Feb 14, 2024 | Initial | $4,818,026 | No comparison | 20 | SEC filing |
| Oct 20, 2021 | Initial | $8,500,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-587364
Source: Form D, filed Jun 15, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Gregory Cresenzi | Executive |
| Matthew Gunnison | Director |
| Jonathan Hartmann | Director, Executive |
| Bryan Hassell | Executive |
| Debrah Herman | Executive |
| John C. Ho | Director |
| David Michael | Director |
| David Seldin | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
44 Manning Rd.
Billerica, MA, 01821
Billerica, MA, 01821